<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258190</url>
  </required_header>
  <id_info>
    <org_study_id>LPR0001</org_study_id>
    <nct_id>NCT03258190</nct_id>
  </id_info>
  <brief_title>Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence</brief_title>
  <official_title>Lime Powder Regimen Supplement Alleviates Urinary Metabolic Abnormalities to Prevent Urolithiasis Recurrence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanpasitthiprasong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Burapha University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lime powder regimen (LPR) is a limeade-derived composition enrichs with citrate/citric acid
      and potassium. LPR was invented to treat the renal stone patients with high risk of stone
      recurrence after stone removal. LPR should have equal or higher efficacy and lower adverse
      effect than current standard medicine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lime powder regimen (LPR) is a mixture of limeade-derive component with adjuvants containing
      high concengtration of citrate, and moderate amount of potassium, magnesium and antioxidants.
      LPR was tested and verified to be very less toxic in cell culture and animal models. The
      clinical trial phase II showed that LPR reduced urinary metabolic abnormalities that enhance
      stone formation, such as hypocitraturia, hypokaliuria and acidified urine. Adverse effect of
      LPR was very low.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2014</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized control trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>LPR and Placebo were prepared in the same containers with code that was provided by investigators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Renal stone recurrence</measure>
    <time_frame>6 months</time_frame>
    <description>The stone recurrenc after surgical removal of stone that can be detected by CT scan</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Lime Powder Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were asked to take LPR twice a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were asked to take Placebo twice a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lime Powder Regimen</intervention_name>
    <description>LPR is limeade-derived component that contain high concentration of citrate and moderate amount of potassium, magnesium and antioxidants</description>
    <arm_group_label>Lime Powder Regimen</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal stone patients who were identified and stone was removed by surgical method.

        Exclusion Criteria:

          -  Chronic kidney disease, chronic liver disease, history of coronary artery disease, or
             person who takes any medication that alters urinary metabolic profiles
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>https://www-ncbi-nlm-nih-gov.cuml1.md.chula.ac.th/pubmed/?term=In+vitro+anti%E2%80%91lithogenic+activity+of+lime+powder+regimen+(LPR)+and+the+effect+of+LPR+on+urinary+risk+factors+for+kidney+stone+formation+in+healthy+volunteers</url>
    <description>Clinical trial phase 1</description>
  </link>
  <results_reference>
    <citation>Chariyavilaskul P, Poungpairoj P, Chaisawadi S, Boonla C, Dissayabutra T, Prapunwattana P, Tosukhowong P. In vitro anti-lithogenic activity of lime powder regimen (LPR) and the effect of LPR on urinary risk factors for kidney stone formation in healthy volunteers. Urolithiasis. 2015 Apr;43(2):125-34. doi: 10.1007/s00240-015-0751-y. Epub 2015 Jan 15.</citation>
    <PMID>25588323</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2017</study_first_submitted>
  <study_first_submitted_qc>August 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>August 20, 2017</last_update_submitted>
  <last_update_submitted_qc>August 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Piyaratana Tosukhowong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Urolithaisis</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Citrate</keyword>
  <keyword>Antioxidants</keyword>
  <keyword>Lime Powder Regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

